MX2023008249A - Forma de dosificacion en tableta solida de ridinilazol. - Google Patents

Forma de dosificacion en tableta solida de ridinilazol.

Info

Publication number
MX2023008249A
MX2023008249A MX2023008249A MX2023008249A MX2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A
Authority
MX
Mexico
Prior art keywords
ridinilazole
solid tablet
benzimidazole
pyridin
dosage form
Prior art date
Application number
MX2023008249A
Other languages
English (en)
Spanish (es)
Inventor
Peter Timmins
Jean-Francois Carniaux
Francis X Wilson
Laura Trespidi
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2023008249A publication Critical patent/MX2023008249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023008249A 2021-01-14 2022-01-14 Forma de dosificacion en tableta solida de ridinilazol. MX2023008249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (1)

Publication Number Publication Date
MX2023008249A true MX2023008249A (es) 2023-07-26

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008249A MX2023008249A (es) 2021-01-14 2022-01-14 Forma de dosificacion en tableta solida de ridinilazol.

Country Status (12)

Country Link
US (1) US12318487B2 (cg-RX-API-DMAC7.html)
EP (1) EP4277604A1 (cg-RX-API-DMAC7.html)
JP (1) JP7862402B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230131253A (cg-RX-API-DMAC7.html)
CN (1) CN116801867A (cg-RX-API-DMAC7.html)
AU (1) AU2022207756B2 (cg-RX-API-DMAC7.html)
CA (1) CA3145677A1 (cg-RX-API-DMAC7.html)
GB (1) GB202100470D0 (cg-RX-API-DMAC7.html)
IL (1) IL304354A (cg-RX-API-DMAC7.html)
MX (1) MX2023008249A (cg-RX-API-DMAC7.html)
WO (1) WO2022153246A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306739B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3696495A (en) 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
PL362691A1 (en) 2000-12-15 2004-11-02 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
AU2003245442B2 (en) 2002-06-13 2009-02-05 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
EP1742637A4 (en) 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
WO2007056330A1 (en) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CN102711739B (zh) * 2009-11-13 2015-12-16 阿斯利康(瑞典)有限公司 双层片剂
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
KR102631986B1 (ko) * 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
CN110809471A (zh) * 2017-04-28 2020-02-18 阿沙纳生物科学公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN111315736B (zh) * 2017-10-05 2023-07-07 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法
CA3106557A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態

Also Published As

Publication number Publication date
WO2022153246A1 (en) 2022-07-21
ZA202306739B (en) 2025-05-28
US20220226249A1 (en) 2022-07-21
CN116801867A (zh) 2023-09-22
EP4277604A1 (en) 2023-11-22
GB202100470D0 (en) 2021-03-03
CA3145677A1 (en) 2022-07-14
AU2022207756A9 (en) 2024-05-09
US12318487B2 (en) 2025-06-03
AU2022207756B2 (en) 2026-01-15
JP7862402B2 (ja) 2026-05-19
AU2022207756A1 (en) 2023-07-27
KR20230131253A (ko) 2023-09-12
JP2024503689A (ja) 2024-01-26
IL304354A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2023001311A (es) Agonistas heterociclicos de glp-1.
PH12022552056A1 (en) Heterocyclic glp-1 agonists
EP4699609A3 (en) Heterocyclic glp-1 agonists
IL326723A (en) 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer
MX2025002170A (es) Inhibidores de kras g12c
EP4306111A3 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ZA202200660B (en) Process for the preparation of ridinilazole and crystalline forms thereof
MX2021013993A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina.
TN2020000159A1 (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
NZ547615A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
WO2006107860A3 (en) Dihydropyridine compounds and compositions for headaches
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
JP2016536363A5 (cg-RX-API-DMAC7.html)
AU2003215672A1 (en) Use of pyridyl amides as inhibitors of angiogenesis
TW200640900A (en) 1-(2h)-isoquinolone derivative
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
PH12022551858A1 (en) Novel heterocyclic compounds useful as aurora a selective inhibitors
UA90763C2 (ru) Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение
TN2016000556A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MY141024A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NO20080033L (no) Kinolinderivater som NK3-antagonister
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.